Which medication would not be classified as a cardioselective beta blocker?

Cardioselective beta blockers primarily target beta-1 adrenergic receptors, which are predominantly located in the heart. This specificity helps to reduce heart rate and myocardial contractility while minimizing effects on beta-2 receptors, which can influence bronchial dilation and vascular smooth muscle.

Propranolol is classified as a non-cardioselective beta blocker because it blocks both beta-1 and beta-2 receptors. This means it can have effects on both the heart and the lungs, which might be beneficial in certain conditions but can also pose risks, particularly in patients with respiratory issues like asthma or COPD, due to its potential to induce bronchoconstriction.

In contrast, medications such as Metoprolol, Atenolol, and Bisoprolol are designed to be cardioselective. They primarily work on beta-1 receptors, making them safer options for patients with respiratory comorbidities while still effectively managing heart conditions such as hypertension and heart failure. Understanding the distinctions between these classes of medications is crucial for safe and effective pharmacological management in patients with cardiovascular issues.